{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:20:38Z","timestamp":1757618438676,"version":"3.44.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01159-z","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T11:47:31Z","timestamp":1751197651000},"page":"543-550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Podcast on Integrating Genetic Testing for Homologous Recombination Repair Gene Alterations in Patients with Prostate Cancer in the USA: a Multidisciplinary Approach to Overcoming the Obstacles"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8336-5010","authenticated-orcid":false,"given":"Brittany M.","family":"Szymaniak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,29]]},"reference":[{"issue":"3","key":"1159_CR1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.21873\/anticanres.16241","volume":"43","author":"IA Voutsadakis","year":"2023","unstructured":"Voutsadakis IA, Stravodimou A. Homologous recombination defects and mutations in DNA damage response (DDR) genes besides BRCA1 and BRCA2 as breast cancer biomarkers for PARP inhibitors and other DDR targeting therapies. Anticancer Res. 2023;43(3):967\u201381.","journal-title":"Anticancer Res"},{"issue":"27","key":"1159_CR2","doi-asserted-by":"publisher","first-page":"10524","DOI":"10.1074\/jbc.TM118.000372","volume":"293","author":"WD Wright","year":"2018","unstructured":"Wright WD, et al. Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018;293(27):10524\u201335.","journal-title":"J Biol Chem"},{"issue":"10","key":"1159_CR3","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, et al. Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983\u201394.","journal-title":"Acta Pharm Sin B."},{"key":"1159_CR4","doi-asserted-by":"publisher","first-page":"1162644","DOI":"10.3389\/fonc.2023.1162644","volume":"13","author":"N Lukashchuk","year":"2023","unstructured":"Lukashchuk N, et al. Impact of DNA damage repair alterations on prostate cancer progression and metastasis. Front Oncol. 2023;13:1162644.","journal-title":"Front Oncol"},{"issue":"6","key":"1159_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro E, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2019;37(6):490\u2013503.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1159_CR6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","volume":"35","author":"D Olmos","year":"2024","unstructured":"Olmos D, et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes. Ann Oncol. 2024;35(5):458\u201372.","journal-title":"Ann Oncol"},{"issue":"4","key":"1159_CR7","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.euo.2020.12.001","volume":"4","author":"Q Karlsson","year":"2021","unstructured":"Karlsson Q, et al. Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL Consortium study. Eur Urol Oncol. 2021;4(4):570\u20139.","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"1159_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","volume":"20","author":"AM Lee","year":"2022","unstructured":"Lee AM, et al. The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer. Clin Genitourin Cancer. 2022;20(6):515\u201323.","journal-title":"Clin Genitourin Cancer"},{"issue":"9","key":"1159_CR9","first-page":"15708","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, et al. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(9):15708\u201315.","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"1159_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","volume":"125","author":"D Wokolorczyk","year":"2021","unstructured":"Wokolorczyk D, et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569\u201375.","journal-title":"Br J Cancer"},{"issue":"5","key":"1159_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.eururo.2020.03.024","volume":"78","author":"B Nguyen","year":"2020","unstructured":"Nguyen B, et al. Pan-cancer analysis of CDK12 alterations identifies a subset of prostate cancers with distinct genomic and clinical characteristics. Eur Urol. 2020;78(5):671\u20139.","journal-title":"Eur Urol"},{"key":"1159_CR12","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer Version 1.2025. 2025. \u00a9National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed 14 April 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"1","key":"1159_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham JA, et al. Clinically localized prostate cancer: AUA\/ASTRO Guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208(1):10\u20138.","journal-title":"J Urol"},{"key":"1159_CR14","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1200\/PO.21.00163","volume":"5","author":"KD Whitaker","year":"2021","unstructured":"Whitaker KD, et al. Cascade genetic testing for hereditary cancer risk: an underutilized tool for cancer prevention. JCO Precis Oncol. 2021;5:1387\u201396.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"1159_CR15","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, et al. Updates to advanced prostate cancer: AUA\/SUO Guideline (2023). J Urol. 2023;209(6):1082\u201390.","journal-title":"J Urol"},{"issue":"1","key":"1159_CR16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JU.0000000000001376","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT, et al. Advanced prostate cancer: AUA\/ASTRO\/SUO Guideline PART II. J Urol. 2021;205(1):22\u20139.","journal-title":"J Urol"},{"key":"1159_CR17","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Version 3.2025. 2025. \u00a9National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed 14 April 2025. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"7","key":"1159_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/jamaoncol.2024.0851","volume":"10","author":"PC Barata","year":"2024","unstructured":"Barata PC, et al. Genetic testing in men with metastatic castration-resistant prostate cancer. JAMA Oncol. 2024;10(7):975\u20137.","journal-title":"JAMA Oncol"},{"issue":"22","key":"1159_CR19","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2217\/fon-2021-0153","volume":"17","author":"N Shore","year":"2021","unstructured":"Shore N, et al. Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. Future Oncol. 2021;17(22):2907\u201321.","journal-title":"Future Oncol"},{"key":"1159_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.826778","volume":"12","author":"T Tang","year":"2022","unstructured":"Tang T, et al. Germline mutations in patients with early-onset prostate cancer. Front Oncol. 2022;12: 826778.","journal-title":"Front Oncol"},{"issue":"5","key":"1159_CR21","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na R, et al. Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol. 2017;71(5):740\u20137.","journal-title":"Eur Urol"},{"issue":"10","key":"1159_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert D, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 2012;106(10):1697\u2013701.","journal-title":"Br J Cancer"},{"issue":"18","key":"1159_CR23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson D, et al. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358\u201365.","journal-title":"J Natl Cancer Inst"},{"issue":"16_suppl","key":"1159_CR24","doi-asserted-by":"publisher","first-page":"5003","DOI":"10.1200\/JCO.2023.41.16_suppl.5003","volume":"41","author":"D Olmos","year":"2023","unstructured":"Olmos D, et al. Presence of somatic\/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first-line (1L) treatment stratified by BRCA status. J Clin Oncol. 2023;41(16_suppl):5003.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1159_CR25","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.3390\/ijms22115522","volume":"22","author":"A Cimadamore","year":"2021","unstructured":"Cimadamore A, et al. Circulating tumor DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic. Int J Mol Sci. 2021;22(11):5522.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1159_CR26","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","volume":"17","author":"HH Cheng","year":"2019","unstructured":"Cheng HH, et al. Germline and somatic mutations in prostate cancer for the clinician. J Natl Compr Canc Netw. 2019;17(5):515\u201321.","journal-title":"J Natl Compr Canc Netw"},{"key":"1159_CR27","doi-asserted-by":"publisher","first-page":"1086517","DOI":"10.3389\/fonc.2023.1086517","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients. Front Oncol. 2023;13:1086517.","journal-title":"Front Oncol"},{"key":"1159_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00567","volume":"8","author":"JJ Park","year":"2024","unstructured":"Park JJ, et al. Repeat next-generation sequencing testing on progression in men with metastatic prostate cancer can identify new actionable alterations. JCO Precis Oncol. 2024;8: e2300567.","journal-title":"JCO Precis Oncol"},{"key":"1159_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-024-00901-4","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ, et al. Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2). Prostate Cancer Prostatic Dis. 2024. https:\/\/doi.org\/10.1038\/s41391-024-00901-4.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"1159_CR30","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"EY Yu","year":"2025","unstructured":"Yu EY, et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO Guideline. J Clin Oncol. 2025;43(6):748\u201358.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1159_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaoncol.2022.5511","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, et al. Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis. JAMA Oncol. 2023;9(2):180\u20137.","journal-title":"JAMA Oncol"},{"key":"1159_CR32","unstructured":"Facing our risk of cancer empowered (FORCE). Deciding about testing. https:\/\/www.facingourrisk.org\/info\/hereditary-cancer-and-genetic-testing\/deciding-about-testing. Accessed 16 April 2025."},{"key":"1159_CR33","unstructured":"American Society of Clinical Oncology. Genetic testing coverage and reimbursement. https:\/\/society.asco.org\/news-initiatives\/current-initiatives\/genetics-toolkit\/genetic-testing-coverage-reimbursement. Accessed 16 April 2025."},{"key":"1159_CR34","unstructured":"National Society of Genetic Counselors. Find a genetic counselor. https:\/\/findageneticcounselor.nsgc.org\/. Accessed 16 April 2025."},{"key":"1159_CR35","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3389\/fgene.2018.00624","volume":"9","author":"S Oliveri","year":"2018","unstructured":"Oliveri S, et al. A systematic review of the psychological implications of genetic testing: a comparative analysis among cardiovascular, neurodegenerative and cancer diseases. Front Genet. 2018;9:624.","journal-title":"Front Genet"},{"key":"1159_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/GO.24.00015","volume":"10","author":"SA Al Sukhun","year":"2024","unstructured":"Al Sukhun SA, et al. Global equity in clinical trials: an ASCO policy statement. JCO Glob Oncol. 2024;10: e2400015.","journal-title":"JCO Glob Oncol"},{"key":"1159_CR37","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1200\/JCO.18.01132","volume":"36","author":"KM Winkfield","year":"2018","unstructured":"Winkfield KM, et al. Addressing financial barriers to patient participation in clinical trials: ASCO policy statement. J Clin Oncol. 2018;36:3331\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1159_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","volume":"30","author":"K Fizazi","year":"2024","unstructured":"Fizazi K, et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nat Med. 2024;30(1):257\u201364.","journal-title":"Nat Med"},{"issue":"22","key":"1159_CR39","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"9","key":"1159_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","volume":"34","author":"KN Chi","year":"2023","unstructured":"Chi KN, et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34(9):772\u201382.","journal-title":"Ann Oncol"},{"key":"1159_CR41","unstructured":"U.S. Food and Drug Administration. RUBRACA\u00ae (rucaparib) prescribing information. Revised September 2023. https:\/\/www.rubracahcp.com\/wp-content\/uploads\/RubracaUSPI.pdf. Accessed 16 April 2025."},{"key":"1159_CR42","unstructured":"U.S. Food and Drug Administration. TALZENNA\u00ae (talazoparib) prescribing information. February 2024. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=11046. Accessed 9 December 2024."},{"key":"1159_CR43","unstructured":"U.S. Food and Drug Administration. LYNPARZA\u00ae (olaparib) prescribing information. Revised November 2023. https:\/\/den8dhaj6zs0e.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/00997c3f-5912-486f-a7db-930b4639cd51\/00997c3f-5912-486f-a7db-930b4639cd51_viewable_rendition__v.pdf. Accessed 16 April 2025."},{"key":"1159_CR44","unstructured":"U.S. Food and Drug Administration. AKEEGATM (niraparib and abiraterone acetate) tablets, for oral use. August 2023. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/AKEEGA-pi.pdf. Accessed 16 April 2025."},{"issue":"9","key":"1159_CR45","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043.","journal-title":"NEJM Evid"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01159-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01159-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01159-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T23:16:05Z","timestamp":1757200565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01159-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,29]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1159"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01159-z","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"type":"print","value":"1776-2596"},{"type":"electronic","value":"1776-260X"}],"subject":[],"published":{"date-parts":[[2025,6,29]]},"assertion":[{"value":"26 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Figshare link\nupdated.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This podcast was funded by Pfizer.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Brittany M.\u00a0Szymaniak reports a consulting role for UroGPO. Alicia K. Morgans has received honoraria from AAA, Astellas Pharma, AstraZeneca, Bayer, Curium, Exelixis, Janssen, Lantheus, MacroGenics, Merck, Novartis, Pfizer, Sanofi, SMPA, and Telix. Neal D. Shore reports a consulting or advisory role for AbbVie, Akido, Alessa Therapeutics, Amgen, Arquer, Asieris, Astellas Pharma, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, CG Oncology, Clarity Pharmaceuticals, Clovis Oncology, Dendreon, Exact Imaging, Exact Sciences, FerGene, Ferring, FIZE Medical, Foundation Medicine, Genentech, GenesisCare, Guardant Health, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, Mdxhealth, Merck, Minomic, Myovant Sciences, Myriad Genetics, Nymox, Pacific Edge Biotechnology, Pfizer, Photocure, PlatformQ, Profound, Promaxo, Propella Therapeutics, Protara, Sanofi, Sesen Bio, Specialty Networks, Telix Pharmaceuticals, Tolmar, UroGen Pharma, Vaxiion, and Vessi; providing expert testimony for Ferring; and leadership or other fiduciary role in another board, society, committee, or advocacy group with Photocure. Neal D. Shore is an Editorial Board member of Targeted Oncology. Neal D. Shore was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the podcast design, outline development, and discussion.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Medical writing support, under the direction of the authors, was provided by Ama Edusei, PharmD, of CMC Connect, a division of IPG Health Medical Communications funded by Pfizer, in accordance with Good Publication Practice (GPP 2022) guidelines. Pfizer\u2019s generative artificial intelligence (AI)\u2013assisted technology was used in the production of this publication to suggest content. After using this tool\/service, the authors reviewed and edited the content as needed, and they take full responsibility for the content of the publication.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Editorial Assistance"}}]}}